AI
AVDL

Atom Investors’s Avadel Pharmaceuticals AVDL Stock Holding History

Atom Investors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,657
Closed -$123K – 506
2024
Q4 		$123K Sell
11,657
-3,547
-23% -$43.1K 0.02% 445
2024
Q3 		$199K Buy
+15,204
New +$232K 0.02% 420
2021
Q4 		– Sell
-75,786
Closed -$743K – 275
2021
Q3 		$743K Sell
75,786
-22,502
-23% -$177K 0.06% 165
2021
Q2 		$661K Buy
98,288
+60,719
+162% +$482K 0.08% 145
2021
Q1 		$340K Buy
+37,569
New +$304K 0.06% 179

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Atom Investors's AVDL Position: Q1 2025 in Review

Atom Investors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 11,657 shares — an estimated $123K sold.

Atom Investors first reported a position in AVDL in Q1 2021 and held it in 5 quarters. The position peaked at $743K in Q3 2021. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • Atom Investors reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Atom Investors sold 11,657 Avadel Pharmaceuticals shares in Q1 2025, an estimated $123K.
  • Atom Investors first reported a position in Avadel Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Atom Investors's Avadel Pharmaceuticals position peaked at $743K in Q3 2021.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Atom Investors's 13F filing for Q1 2025, filed 15 May 2025.